Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, James N. Kochenderfer, Yi Lin et al.|New England Journal of Medicine|2019Cited by 1.7k
Toxicities of chimeric antigen receptor T cells: recognition and managementJennifer N. Brudno, James N. Kochenderfer|Blood|2016Cited by 1.4k
Long-term outcomes following CAR T cell therapy: what we know so farKathryn M. Cappell, James N. Kochenderfer|Nature Reviews Clinical Oncology|2023Cited by 1.2k
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsJames N. Kochenderfer, Steven A. Rosenberg|Blood|2010Cited by 387
Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domainsNorris Lam, James N. Kochenderfer|Nature Communications|2020Cited by 123